Prescription pricing runs through a chain of intermediaries, and understanding it explains why the same medication can cost wildly different amounts.
The intermediary role
Benefit managers negotiate with manufacturers on behalf of insurers and employers.
Which determines which drugs are covered and at what cost sharing.
Formularies — the covered drug lists — are the operative document.
Rebates
Manufacturers pay rebates to secure formulary placement.
Which are negotiated confidentially.
List prices and net prices after rebates have diverged substantially over time.
Why list prices rise
Rebates are frequently calculated as a percentage of list price.
Which creates an incentive for higher list prices with larger rebates.
Patients whose cost sharing is based on list price pay more as a result.
Cost sharing
Copayments, coinsurance and deductibles determine what a patient actually pays.
Which varies by plan and by where a drug sits on the formulary.
Coinsurance based on list price rather than net price is a documented source of high patient costs.
Cash prices
Paying without using insurance is sometimes cheaper.
Which particularly applies to generics.
Discount card programmes and direct cash pricing have grown for this reason.
Pharmacy reimbursement
What pharmacies receive is negotiated separately.
Which has produced disputes over reimbursement below acquisition cost.
Independent pharmacy closures have been attributed partly to this.
Regulatory attention
Transparency requirements and investigations into the intermediary sector have increased.
Which has produced reports setting out the flows in detail.
Several states have enacted legislation regulating these arrangements.
What patients can do
Ask the pharmacy for the cash price, compare against your copayment, and check whether a generic exists.
Pharmacists can generally discuss this and are the practical source of advice.
Vertical integration
Benefit managers, insurers, pharmacies and providers under common ownership.
Which has attracted competition scrutiny.
The structure creates incentives that are difficult to observe from outside.
Spread pricing
Charging the plan more than the pharmacy is reimbursed and retaining the difference.
Which several states have restricted or prohibited in public programmes.
Transparency requirements have been introduced in response.
Manufacturer coupons
Reducing patient cost sharing for branded drugs.
Which insurers have restricted through accumulator programmes.
These do not apply the coupon value toward a deductible, which affects patients materially.
Biosimilar adoption
Lower-cost alternatives to biologics.
Which have been adopted more slowly than generics were.
Formulary placement decisions have been a significant factor in that pace.
Practical steps
Ask about cash price, generic alternatives and manufacturer assistance programmes.
Insulin and high-cost drugs
Cost sharing for chronic medications has produced documented rationing behaviour.
Which has driven policy responses including price caps in some programmes.
Manufacturer price reductions on some products followed sustained public attention.
Formulary exclusions
Drugs removed from coverage lists annually.
Which forces switching for patients stabilised on a medication.
Exception processes exist and require prescriber involvement.
Prior authorisation
Requiring approval before a prescription is covered.
Which delays treatment and is a documented administrative burden.
Reform of these processes has been legislated in several states.
Independent pharmacies
Reimbursement rates and fees have been cited in closure decisions.
Which reduces access particularly in rural areas.
State legislation regulating reimbursement has been enacted in response.
What to ask
Cash price, generic availability, therapeutic alternatives and manufacturer assistance.
Why the system is opaque
Rebates are confidential, contracts are confidential, and the parties negotiating have no interest in disclosure.
That opacity is the subject of most current reform proposals, and transparency requirements have been enacted in several states.
What a patient can actually do
Ask for the cash price, ask about generics and therapeutic alternatives, and ask the pharmacist directly.
Where to read the analysis
Regulatory investigations and government reports have set out the flows and the incentives in detail.
Which are freely available and considerably more informative than industry material from any side.
State legislative activity in this area is also documented publicly.
The patient's practical position
Compare cash and insured prices, ask about alternatives, and involve the pharmacist.
A closing thought
A patient at a counter is at the end of a chain of confidential negotiations that determine what they pay, none of which they can see.
Asking the pharmacist about cash prices and alternatives is the one point in that chain where an individual has any leverage.
Employer plan design
Employers choose plan structures that determine employee cost sharing.
Which is where much of the variation in what people pay originates.
Plan documents set out formulary tiers and cost sharing and are provided to members.
Mail order requirements
Some plans require or incentivise mail order for maintenance medications.
Which reduces cost and removes local pharmacy contact.
Exceptions are generally available on request.
The last word
Almost nobody at a pharmacy counter knows why their medication costs what it does, and the reason is a chain of confidential negotiations upstream.
Asking about cash prices and alternatives is the only lever available at that point, and it works more often than people expect.